Generic Viberzi Availability
Last updated on Jul 9, 2025.
Viberzi is a brand name of eluxadoline, approved by the FDA in the following formulation(s):
VIBERZI (eluxadoline - tablet;oral)
Is there a generic version of Viberzi available?
A generic version of Viberzi has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Viberzi and have been approved by the FDA:
eluxadoline tablet;oral
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Viberzi. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Opioid receptor modulator dosage formulations
Patent 10,188,632
Issued: January 29, 2019
Inventor(s): Costello Tim & Ceulemans Jens Jozef & Jans Eugeen Maria Jozef & Heyns Philip Erna H.
Assignee(s): Allergan Holdings Unlimited CompanyAbuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.
Patent expiration dates:
- March 14, 2033✓
- March 14, 2033
-
Compounds as opioid receptor modulators
Patent 10,213,415
Issued: February 26, 2019
Inventor(s): Breslin Henry J. & Cai Chaozhong & He Wei & Kavash Robert W.
Assignee(s): Janssen Pharmaceutica NVThe present invention is directed to novel opioid receptor modulators of Formula (I).
Patent expiration dates:
- March 14, 2025✓✓
- March 14, 2025
-
Opioid receptor modulator dosage formulations
Patent 11,007,179
Issued: May 18, 2021
Inventor(s): Costello Tim & Ceulemans Jens Jozef & Jans Eugeen Maria Jozef & Heyns Philip Erna H.
Assignee(s): Allergan Holdings Unlimited CompanyAbuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-4,5-dihydro-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.
Patent expiration dates:
- March 14, 2033✓
- March 14, 2033
-
Opioid receptor modulator dosage formulations
Patent 11,090,291
Issued: August 17, 2021
Inventor(s): Costello Tim & Ceulemans Jens Jozef & Jans Eugeen Maria Jozef & Heyns Philip Erna H.
Assignee(s): Allergan Holdings Unlimited CompanyAbuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.
Patent expiration dates:
- March 14, 2033✓
- March 14, 2033
-
Opioid receptor modulator dosage formulations
Patent 11,160,792
Issued: November 2, 2021
Inventor(s): Costello Tim & Ceulemans Jens Jozef & Jans Eugeen Maria Jozef & Heyns Philip Erna H.
Assignee(s): Allergan Holdings Unlimited CompanyAbuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.
Patent expiration dates:
- March 14, 2033✓
- March 14, 2033
-
Opioid receptor modulator dosage formulations
Patent 11,229,627
Issued: January 25, 2022
Inventor(s): Costello Tim & Ceulemans Jens Jozef & Jans Eugeen Maria Jozef & Heyns Philip Erna H.
Assignee(s): Allergan Holdings Unlimited CompanyAbuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.
Patent expiration dates:
- March 14, 2033✓
- March 14, 2033
-
Opioid receptor modulator dosage formulations
Patent 11,311,516
Issued: April 26, 2022
Inventor(s): Costello; Tim et al.
Assignee(s): Allergan Holdings Unlimited Company (Dublin, IE)Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.
Patent expiration dates:
- March 14, 2033✓
- March 14, 2033
-
Opioid receptor modulator dosage formulations
Patent 11,484,527
Issued: November 1, 2022
Inventor(s): Costello; Tim et al.
Assignee(s): Allergan Holdings Unlimited Company (Dublin, IE)Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.
Patent expiration dates:
- March 14, 2033✓
- March 14, 2033
-
Opioid receptor modulator dosage formulations
Patent 12,097,187
Issued: September 24, 2024
Inventor(s): Costello; Tim et al.
Assignee(s): Allergan Holdings Unlimited Company (Dublin, IE)Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6 -dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy -benzoic acid, and processes for the preparation and administration of these formulations.
Patent expiration dates:
- March 14, 2033✓
- March 14, 2033
-
Compounds as opioid receptor modulators
Patent 7,741,356
Issued: June 22, 2010
Inventor(s): Breslin; Henry J. et al.
Assignee(s): Janssen Pharmaceutica N.V. (Beerse, BE)The present invention is directed to novel opioid receptor modulators of Formula (I). ##STR00001## The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may be ameliorated or treated by the modulation of opioid receptors.
Patent expiration dates:
- May 27, 2029✓✓
- May 27, 2029
-
Compounds as opioid receptor modulators
Patent 7,786,158
Issued: August 31, 2010
Inventor(s): Breslin; Henry J. et al.
Assignee(s): Janssen Pharmaceutica N.V. (Beerse, BE)The present invention is directed to novel opioid receptor modulators of Formula (I). ##STR00001## The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may be ameliorated or treated by the modulation of opioid receptors.
Patent expiration dates:
- March 14, 2025✓
- March 14, 2025
-
Compounds as opioid receptor modulators
Patent 8,344,011
Issued: January 1, 2013
Inventor(s): Breslin Henry J. & Cai Chaozhong & He Wei & Kavash Robert W.
Assignee(s): Janssen Pharmaceutica, N.V.The present invention is directed to novel opioid receptor modulators of Formula (I).
Patent expiration dates:
- March 14, 2025✓
- March 14, 2025
-
Compounds as opioid receptor modulators
Patent 8,609,709
Issued: December 17, 2013
Inventor(s): Breslin Henry J. & Cai Chaozhong & He Wei & Kavash Robert W.
Assignee(s): Janssen Pharmaceutica, N. V.The present invention is directed to novel opioid receptor modulators of Formula (I).
Patent expiration dates:
- March 14, 2025✓
- March 14, 2025
-
Crystals and process of making 5-({(2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(-4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
Patent 8,691,860
Issued: April 8, 2014
Inventor(s): Anzalone Luigi & Villani Frank J. & Teleha Christopher A. & Feibush Penina & Fegely Barry
Assignee(s): Furiex Pharmaceuticals, Inc.The present invention relates to a novel crystals of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid and methods of making the zwitterion of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid.
Patent expiration dates:
- July 7, 2028✓✓
- July 7, 2028
-
Compounds as opioid receptor modulators
Patent 8,772,325
Issued: July 8, 2014
Inventor(s): Breslin Henry J. & Cai Chaozhong & He Wei & Kavash Robert W.
Assignee(s): Janssen Pharmaceutica, N.V.The present invention is directed to novel opioid receptor modulators of Formula (I).
Patent expiration dates:
- March 14, 2025✓
- March 14, 2025
-
Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl—1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
Patent 9,115,091
Issued: August 25, 2015
Inventor(s): Anzalone Luigi & Villani Frank J. & Teleha Christopher A. & Feibush Penina & Fegely Barry
Assignee(s): FURIEX PHARMACEUTICALS, INC.The present invention relates to a novel crystals of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid and methods of making the zwitterion of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid.
Patent expiration dates:
- July 7, 2028✓✓✓
- July 7, 2028
-
Compounds as opioid receptor modulators
Patent 9,205,076
Issued: December 8, 2015
Inventor(s): Breslin Henry J. & Cai Chaozhong & He Wei & Kavash Robert W.
Assignee(s): Janssen Pharmaceutica, N.V.The present invention is directed to novel opioid receptor modulators of Formula (I).
Patent expiration dates:
- March 14, 2025✓
- March 14, 2025
-
Crystals and process of making 5-({[2-amino-3-(4-Carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
Patent 9,364,489
Issued: June 14, 2016
Inventor(s): Anzalone Luigi & Villani Frank J. & Teleha Christopher A. & Feibush Penina & Fegely Barry
Assignee(s): Forest Tosara LimitedThe present invention relates to a novel crystals of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid and methods of making the zwitterion of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid.
Patent expiration dates:
- July 7, 2028✓
- July 7, 2028
-
Opioid receptor modulator dosage formulations
Patent 9,675,587
Issued: June 13, 2017
Inventor(s): Costello Tim & Ceulemans Jens Jozef & Jans Eugeen Maria Jozef & Heyns Philip Erna H.
Assignee(s): Allergan Holdings Unlimited CompanyAbuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.
Patent expiration dates:
- March 14, 2033✓
- March 14, 2033
-
Compounds as opioid receptor modulators
Patent 9,700,542
Issued: July 11, 2017
Inventor(s): Breslin Henry J. & Cai Chaozhong & He Wei & Kavash Robert W.
Assignee(s): Janssen Pharmaceutica NVThe present invention is directed to novel opioid receptor modulators of Formula (I).
Patent expiration dates:
- March 14, 2025✓
- March 14, 2025
-
Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
Patent 9,789,125
Issued: October 17, 2017
Inventor(s): Anzalone Luigi & Villani Frank J. & Teleha Christopher A. & Feibush Penina & Fegely Barry
Assignee(s): Allergan Holdings Unlimited CompanyThe present invention relates to a novel crystals of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid and methods of making the zwitterion of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid.
Patent expiration dates:
- July 7, 2028✓✓
- July 7, 2028✓✓
- July 7, 2028
More about Viberzi (eluxadoline)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (217)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: peripheral opioid receptor mixed agonists/antagonists
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Related/similar drugs
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
| AB | Products meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (e.g. identical active ingredients, dosage form, and routes of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (e.g. AB1, AB2, AB7). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
